Clinical Scorecard: Beyond IOP: The Mood Effects of CAIs
At a Glance
| Category | Detail |
|---|---|
| Condition | Glaucoma |
| Key Mechanisms | Topical carbonic anhydrase inhibitors (CAIs) may contribute to depressive symptoms through systemic absorption. |
| Target Population | Patients with glaucoma, particularly those with a history of depression or anxiety. |
| Care Setting | Ophthalmology clinics |
Key Highlights
- Topical CAIs associated with a 25–35% higher hazard of depression.
- Nearly twofold increase in likelihood of antidepressant initiation after CAI treatment.
- Symptoms may emerge as early as three months after starting CAIs.
- Increased vigilance recommended for patients with prior mental health issues.
- Automated EHR-based AI tools may help identify psychiatric distress.
Guideline-Based Recommendations
Diagnosis
- Consider the temporal relationship between CAI initiation and onset of depressive symptoms.
Management
- Monitor for neuropsychiatric symptoms after initiating topical CAIs.
Monitoring & Follow-up
- Routine screening for depression or anxiety is encouraged, especially in the first months.
Risks
- Increased risk of depression in patients with prior mental health issues or on psychotropic medications.
Patient & Prescribing Data
Patients with glaucoma, especially older adults and those with multiple comorbidities.
Discontinue CAIs if depressive symptoms arise; monitor closely during initial treatment phase.
Clinical Best Practices
- Engage in open dialogue about mental health with glaucoma patients.
- Utilize AI tools for identifying at-risk patients without burdening clinical workflow.
- Be vigilant in prescribing CAIs to patients with a history of depression or anxiety.
References
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
